Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing
terms of pharmacokinetics, safety, tolerability and immunogenicity. In the treatment of active ankylosing spondylitis, Taibowei has outperformed the original adalimumab in terms of liver safety. The original adalimumab has been the world's top-selling drug for nine years; however, in the PRC, due to relatively
less approved indications, high selling price and other factors, the usage rate of the drug among Chinese patients is less than 2%. The approval for launch of Taibowei will greatly improve the drug accessibility of patients at a competitive market price. In addition, the Group is currently the only pharmaceutical company with both small molecule (tofacitinib) and macromolecule (adalimumab) anti-rheumatic drugs in the PRC. These two types of anti-rheumatic drugs with different mechanisms can complement each other in clinical use to satisfy the different treatment needs of a wider range of patients. The Group will capitalize on the trend of "care for comorbidity" to promote the "integration of diagnosis and treatment" of orthopedics and rheumatology and the expansion of new patients, with a view to benefiting more patients.